> Lighter regulation around rare "small market" diseases might save a lot of lives. And money. Orphan drugs for rare diseases are already subject to less regul

> Lighter regulation around rare "small market" diseases might save a lot of lives. And money. Orphan drugs for rare diseases are already subject to less regulation.